Fragment-based hit identification: thinking in 3D

Andrew D. Morley; Angelo Pugliese; Kristian Birchall; Justin Bower; Paul Brennan; Nathan Brown; Tim Chapman; Martin Drysdale; Ian H. Gilbert; Swen Hoelder; Allan Jordan; Steven V. Ley; Andy Merritt; David Miller; Martin E. Swarbrick; Paul G. Wyatt

doi:10.1016/j.drudis.2013.07.011

Fragment-based hit identification: thinking in 3D

Andrew D. Morley (Lead / Corresponding author)
, Angelo Pugliese
, Kristian Birchall
, Justin Bower
, Paul Brennan
, Nathan Brown
, Tim Chapman
, Martin Drysdale
, Ian H. Gilbert
, Swen Hoelder
, Allan Jordan
, Steven V. Ley
, Andy Merritt
, David Miller
, Martin E. Swarbrick
, Paul G. Wyatt (Lead / Corresponding author)

Research output: Contribution to journal › Article › peer-review

153 Citations (Scopus)

Abstract

The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.

Original language	English
Pages (from-to)	1221-1227
Number of pages	7
Journal	Drug Discovery Today
Volume	18
Issue number	23-24
DOIs	https://doi.org/10.1016/j.drudis.2013.07.011
Publication status	Published - Dec 2013

Access to Document

10.1016/j.drudis.2013.07.011

Cite this

@article{f99f514a6bc740729ecc25697dfd4d5e,

title = "Fragment-based hit identification: thinking in 3D",

abstract = "The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.",

author = "Morley, \{Andrew D.\} and Angelo Pugliese and Kristian Birchall and Justin Bower and Paul Brennan and Nathan Brown and Tim Chapman and Martin Drysdale and Gilbert, \{Ian H.\} and Swen Hoelder and Allan Jordan and Ley, \{Steven V.\} and Andy Merritt and David Miller and Swarbrick, \{Martin E.\} and Wyatt, \{Paul G.\}",

year = "2013",

month = dec,

doi = "10.1016/j.drudis.2013.07.011",

language = "English",

volume = "18",

pages = "1221--1227",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier",

number = "23-24",

}

TY - JOUR

T1 - Fragment-based hit identification

T2 - thinking in 3D

AU - Morley, Andrew D.

AU - Pugliese, Angelo

AU - Birchall, Kristian

AU - Bower, Justin

AU - Brennan, Paul

AU - Brown, Nathan

AU - Chapman, Tim

AU - Drysdale, Martin

AU - Gilbert, Ian H.

AU - Hoelder, Swen

AU - Jordan, Allan

AU - Ley, Steven V.

AU - Merritt, Andy

AU - Miller, David

AU - Swarbrick, Martin E.

AU - Wyatt, Paul G.

PY - 2013/12

Y1 - 2013/12

N2 - The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.

AB - The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.

U2 - 10.1016/j.drudis.2013.07.011

DO - 10.1016/j.drudis.2013.07.011

M3 - Article

C2 - 23906694

SN - 1359-6446

VL - 18

SP - 1221

EP - 1227

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 23-24

ER -

Fragment-based hit identification: thinking in 3D

Abstract

Access to Document

Fingerprint

Cite this